Duopharma Biotech Bhd

Duopharma Biotech Bhd Current Liabilities

The Current Liabilities of Duopharma Biotech Bhd (DPHARMA.KL) as of Nov 3, 2026 is 177.99 M MYR. In the previous year, Current Liabilities was 166.73 M MYR — a change of 6.75% (higher).

Current Liabilities

177.99 MMYR

YoY

6.75%

Last updated:

Current Liabilities of Duopharma Biotech Bhd is 2024 177.99 M MYR. Current Liabilities of Duopharma Biotech Bhd was 2023 166.73 M MYR. It decreases by 6.75% higher compared to the previous year.

The Duopharma Biotech Bhd Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2017
121.66 M MYR
Jan 1, 2018
222.45 M MYR
Jan 1, 2019
239.44 M MYR
Jan 1, 2020
150.32 M MYR
Jan 1, 2021
230.31 M MYR
Jan 1, 2022
264.59 M MYR
Jan 1, 2023
166.73 M MYR
Jan 1, 2024
177.99 M MYR
The Duopharma Biotech Bhd Current Liabilities history
YEARCurrent LiabilitiesYoY
177.99 MMYR+6.75%
166.73 MMYR-36.99%
264.59 MMYR+14.89%
230.31 MMYR+53.21%
150.32 MMYR-37.22%
239.44 MMYR+7.64%
222.45 MMYR+82.84%
121.66 MMYR+17.94%
103.16 MMYR+38.07%
74.71 MMYR+220.01%
23.35 MMYR+25.52%
18.60 MMYR-15.45%
22.00 MMYR-13.04%
25.30 MMYR+4.12%
24.30 MMYR+42.94%
17.00 MMYR+6.25%
16.00 MMYR+70.21%
9.40 MMYR-12.96%
10.80 MMYR+35.00%
8.00 MMYR-5.88%
8.50 MMYR+6.25%
8.00 MMYR+42.86%
5.60 MMYR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Duopharma Biotech Bhd Stock analysis

What does Duopharma Biotech Bhd do? Duopharma Biotech Bhd generates revenue through its three business segments: Consumer Healthcare (CHC), Ethical Classic Business (ECB), and Ethical Specialty Business (ESB). The CHC segment sells over-the-counter products like vitamins, supplements, analgesics, eyecare, and antacids under brands such as Flavettes, CHAMPS, Uphamol, and Eye Glo to domestic, regional, and international markets. The ECB segment produces over 300 generic drugs including Crystorvas, Prelica, and Omesec, targeting healthcare providers and pharmacies. The ESB segment focuses on specialized drugs, medical devices, and consumables, while also commercializing biosimilars like ERYSAA, Basalog One, and Zuhera through international partnerships. The company's products are distributed across multiple markets, with CHC brands reaching consumers directly through retail channels. ECB drugs are supplied to healthcare institutions and pharmacies, while ESB products target specialized medical needs. Biosimilar collaborations with international partners enable the company to expand its portfolio beyond traditional pharmaceuticals, enhancing its market presence in both domestic and global segments. Duopharma Biotech Bhd's revenue streams are diversified across consumer-facing CHC products, generic ECB drugs, and specialized ESB solutions. The company leverages its established brands and partnerships to serve both mass-market and niche healthcare segments, ensuring steady demand for its pharmaceutical offerings in Malaysia and beyond. Duopharma Biotech Bhd is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Duopharma Biotech Bhd stock

Current Liabilities of Duopharma Biotech Bhd is 177.99 M MYR in 2024.

Current Liabilities of Duopharma Biotech Bhd changed from 166.73 M MYR to 177.99 M MYR, representing a 6.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Duopharma Biotech Bhd since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's MYR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Duopharma Biotech Bhd historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Duopharma Biotech Bhd

All Key Metrics — Duopharma Biotech Bhd